Under construction – not a live service
Sign in
Taking peopleNo phase

CArdiac STereotactic Radiation Treatment for Ablation of ventRicular Tachycardia

Key facts

Who runs it
Cancer Research Antwerp
Where
Belgium2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
20 people, planned
Started
25 Feb 2026
Expected to end
25 Feb 2035
Type of study
Interventional
Treatments tested
  • Stereotactic body radiation therapy (SBRT)
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients over the age of 18 with structural heart disease
  • Patients with ventricular tachycardia requiring intervention (e.g. an electrical shock or anti-tachycardia pacing via an Implantable Cardioverter Defibrillator (ICD)) which cannot be managed with medication or catheter ablation, or where there are contraindications to treatment with medication or catheter ablation
  • Contraindications may exist due to comorbidities or due to the type or severity of the disease
  • Informed consent to participate has been obtained from the patient or from his or her legal representative

Who cannot take part

  • Previous radiotherapy that prevents the safe delivery of the dose
  • Lack of evidence that the ventricular tachycardia is triggered by myocardial scarring (based on MRI, CT EAM)
  • Any contraindication to radiosurgery (e.g. inability to precisely define the target volume due to imaging artefacts caused by an LVAD)
  • Pregnancy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigator-initiated, CArdiac Stereotactic radiation Treatment for Ablation of ventRicular tachycardia (CASTAR) study will be conducted in patients with ventricular tachycardia (VT) which is either refractory to antiarrhythmic medication therapy in maximal dose or to catheter ablation or with contraindications to antiarrhythmic medication or catheter ablation.

Read full original descriptionShow less

The study is a non-randomized, multicenter, interventional study of cardiac SBRT, for which a total dose of 25 Gy will be delivered in a single fraction using volumetric modulated arc therapy (VMAT). The aim of the CASTAR study is to assess the feasibility and the safety of cardiac SBRT for the treatment of VT. Secondary objectives are efficacy, toxicity and QoL of cardiac SBRT for Ventricular tachycardia .

The group in the trial

  • SBRTTreatment being tested

    A single radiation dose of 25 Gy is delivered to the VT target.

    Treatment: Stereotactic body radiation therapy (SBRT)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
12 November 2026